Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 20, 2005. The filing discloses the entry into a material definitive agreement regarding the company's existing credit facilities.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or total debt. The only financial metric disclosed is a fee structure related to the amendment of the Loan and Security Agreement with Lighthouse Capital Partners V, L.P.
- Fee Obligation: Alnylam agreed to pay a fee equal to 0.75% of the remaining dollar amount of the Commitment as of October 1, 2005.
Material Changes
The primary material change is the extension of the draw-down period for Alnylam's line of credit with Lighthouse Capital Partners V, L.P.
- Previous Term: Ability to draw down funds through June 30, 2005.
- New Term: Ability to draw down funds extended through January 1, 2006.
Outlook, Risks, and Management Commentary
Management commentary is limited to the execution of Amendment No. 02 to the Loan and Security Agreement dated March 26, 2004. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the conditions required to adhere to the amended loan terms.
Investor Verification Checklist
- Verify the total dollar amount of the "Commitment" under the Loan Agreement to calculate the potential 0.75% fee due on October 1, 2005.
- Confirm whether Alnylam has met the "certain conditions" required to exercise the draw-down ability through the new January 1, 2006 deadline.
- Review the full text of Amendment No. 02 (Exhibit 10.1) for any additional covenants or restrictions not summarized in this report.